Search
 
News

Big Pharma's Shkreli sentenced to seven years in prison

The sentence puts an end to a saga that captivated and sometimes enraged Washington, Wall Street and the tabloids.

By Patricia Hurtado and Erik Larson | Updated on March 09, 2018
Photo of Martin Shkreli The brash 34-year-old gained notoriety for jacking up the price of a life-saving anti-infection drug. (Photo: Victor J. Blue/Bloomberg)

Martin Shkreli, the pharmaceutical industry’s enfant terrible, was sentenced Friday to seven years in prison, putting an end to a saga that captivated and sometimes enraged Washington, Wall Street and the tabloids.

The brash 34-year-old — who gained notoriety for jacking up the price of a life-saving anti-infection drug — was convicted in August of lying to investors in his hedge funds and manipulating shares in Retrophin Inc., a biotech company he founded. Prosecutors sought a sentence of at least 15 years for the securities fraud. Shkreli, who once proclaimed “you can’t quell the Shkrel,” asked for as little as a year. “This case is not about Mr. Shkreli’s self-cultivated public persona,” U.S. District Judge Kiyo Matsumoto in Brooklyn, New York, said Friday before handing down the sentence. His actions were “extremely serious,” she said, recounting how he boasted once of threatening an investor and his family.

Complete your profile to continue reading and get FREE access to BenefitsPRO.com, part of your ALM digital membership.

Your access to unlimited BenefitsPRO.com content isn’t changing.
Once you are an ALM digital member, you’ll receive:

  • Critical BenefitsPRO.com information including cutting edge post-reform success strategies, access to educational webcasts and videos, resources from industry leaders, and informative Newsletters.
  • Exclusive discounts on ALM, BenefitsPRO magazine and BenefitsPRO.com events.
  • Access to other award-winning ALM websites including ThinkAdvisor.com and Law.com

Already have an account?

NOT FOR REPRINT

© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.

Recommended Stories

BenefitsPRO

Join BenefitsPRO

Don’t miss crucial news and insights you need to navigate the shifting employee benefits industry. Join BenefitsPRO.com now!

  • Unlimited access to BenefitsPRO.com - your roadmap to thriving in a disrupted environment
  • Access to other award-winning ALM websites including ThinkAdvisor.com and Law.com
  • Exclusive discounts on BenefitsPRO.com and ALM events.

Already have an account? Sign In Now
Join BenefitsPRO

Copyright © 2024 ALM Global, LLC. All Rights Reserved.